<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01028326</url>
  </required_header>
  <id_info>
    <org_study_id>SSC 1635</org_study_id>
    <nct_id>NCT01028326</nct_id>
  </id_info>
  <brief_title>PCV10 Reactogenicity and Immunogenicity Study - Malindi</brief_title>
  <acronym>PRISM</acronym>
  <official_title>Immunogenicity and Reactogenicity of 10-valent Pneumococcal Conjugate Vaccine (PCV10) in Children Aged 12-59 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KEMRI-Wellcome Trust Collaborative Research Program</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kenya Ministry of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KEMRI-Wellcome Trust Collaborative Research Program</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The World Health Organization has recommended that developing countries should incorporate
      pneumococcal conjugate vaccine (PCV) into their routine immunization schedules. The Kenya
      Ministry of Health anticipates introducing a new formulation of PCV, PCV10, into the routine
      childhood immunization schedule in 2010. In the areas of Kenya that have been designated to
      monitor the impact of vaccine, a catch-up campaign will be implemented to vaccinate children
      aged 12-59 months. PCV10 has been found to be safe and effective in infants. It is licensed
      for use in children up to 2 years of age, but its use as a primary series in children over
      age 12 months has not been evaluated. This study will assess the immunogenicity and
      reactogenicity of PCV10 first administered at an age of 12-59 months.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serotype-specific anti-pneumococcal antibody responses to vaccination</measure>
    <time_frame>Day 0, 30, 90, 210</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serotype-specific NP carriage of pneumococci</measure>
    <time_frame>Day 0, 30, 60, 90, 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine reactogenicity</measure>
    <time_frame>Day 0, 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological memory responses</measure>
    <time_frame>Day 0, 30, 90, 210</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Pneumococcal Pneumonia</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A of children will receive 2 doses of PCV10 vaccine, one at the time of enrolment and one 2 months later, followed by a dose of DTaP vaccine 4 months later</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B of children will receive PCV10 vaccine, followed by a dose of DTaP vaccine after 2 months, and another dose of PCV10 4 months later.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group C of children will receive a dose of hepatitis A vaccine, followed by a dose of DTaP vaccine after 2 months, and another dose of hepatitis A 4 months later, along with a dose of PCV10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCV10 and DTaP</intervention_name>
    <description>A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 60 and a 0.5 mL intramuscular dose of DTaP on day 180.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Synflorix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PCV10 and DTaP</intervention_name>
    <description>A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 180 and a 0.5 mL dose of DTaP on day 60.</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Synflorix</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hepatitis A vaccine, DTaP, PCV10</intervention_name>
    <description>A nurse will administer a 0.5mL intramuscular dose of hepatitis A vaccine on day 0 and day 180; a 0.5 mL intramuscular dose of DTaP on day 60; and a 0.5 mL dose of PCV10 on day 180.</description>
    <arm_group_label>Group C</arm_group_label>
    <other_name>Synflorix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 12-59 months

          -  Written informed consent

        Exclusion Criteria:

          -  Current febrile illness (temperature &gt;38.5Â°C)

          -  Previous receipt of any pneumococcal vaccine

          -  Previous receipt of a DTP-containing vaccine after the 1st year of life

          -  Previous receipt of hepatitis A vaccine

          -  Severe malnutrition (mid upper arm circumference &lt;11.5 cm) or other serious medical
             condition (e.g., malignancy, AIDS, tuberculosis)

          -  Seizures within the previous 6 months or progressive neurological illness

          -  Known allergies to vaccines or vaccine components

          -  Resident in the Kilifi Demographic Surveillance area

          -  Intention to leave the study area in the next 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>59 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Hammitt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University, KEMRI-Wellcome Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Malindi District Hospital</name>
      <address>
        <city>Malindi</city>
        <state>Coast</state>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2009</study_first_submitted>
  <study_first_submitted_qc>December 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2009</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pneumococcal pneumonia vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

